MAPI Pharma Group is a new multi national company in Israel, Germany, HK and China, and is developing a unique and novel way of tapping the API (Active Pharmaceutical Ingredient) market for Generic Pharmaceuticals, and then develops the most effective route of production, and physical form of the API production will be done in new plants in China and Germany.
MAPI Pharma Group will be one of the leading players in the API markets. Using its excellent networking in these territories, MAPI will provide generic intermediates & API\'s and in parallel will develop finish dosage forms either to MAPI\'s API\'s, as a vertically integrated company and generic to other leading brands. These dosage forms might be simple or complex generics like controlled release. At the beginning, MAPI will focus on intermediates & API\'s forms which represent about 80% of the pharmaceutical market as well as intermediate API for pharmaceuticals.
The Company will develop more than 20 new advanced generic Intermediates and API\'s for which their patents will expire till 2020, and also will develop new patents, as well as at an estimated rate of 2-3 new molecules per annum.
